Comprehensive medication guide to Milnacipran including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
Most commercial plans place Milnacipran (Savella) on Tier 3–4, requiring prior authorization and step therapy. With insurance plus the Savella Savings Card, eligible patients may pay as little as $20 per fill. Medicare patients are not eligible for the manufacturer card and may face higher out-of-pocket costs depending on their Part D plan.
Estimated Cash Pricing
Brand-name Savella retails at $466–$766 for a 30-day supply (60 tablets at 50 mg); with a SingleCare or GoodRx coupon, prices drop to approximately $39–$60. Generic milnacipran, when available, costs less. Commercially insured patients may pay as little as $20/month with the Savella Savings Card.
Medfinder Findability Score
72/100
Summarize with AI
On this page
Milnacipran is the generic name for the brand-name drug Savella. It is a serotonin-norepinephrine reuptake inhibitor (SNRI) and one of only three FDA-approved medications for fibromyalgia in the United States. The FDA granted approval in January 2009 for the management of fibromyalgia in adults. Unlike related SNRIs such as duloxetine and venlafaxine, Milnacipran is not FDA-approved for depression in the United States — though it is used for this purpose in Europe and other countries.
Milnacipran is not a controlled substance and can be prescribed by any licensed healthcare provider, including via telehealth. It is available as film-coated tablets in strengths of 12.5 mg, 25 mg, 50 mg, and 100 mg. Generic milnacipran received FDA approval and first entered the U.S. market in November 2017, though retail availability has been inconsistent.
Fibromyalgia affects an estimated 4 million Americans, causing widespread chronic pain, fatigue, sleep disturbances, and cognitive difficulties. It is diagnosed clinically — without definitive blood tests or imaging — based on symptom criteria. Milnacipran targets the central pain processing dysfunction that underlies fibromyalgia rather than peripheral tissue damage.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Milnacipran works by blocking the reuptake of two neurotransmitters — serotonin and norepinephrine — in the synaptic space between neurons. By preventing these chemicals from being reabsorbed by the sending nerve cell, Milnacipran increases their availability at the synapse, amplifying their effect on pain-regulating pathways in the brain and spinal cord.
Milnacipran is distinctive among SNRIs for its preferential inhibition of norepinephrine over serotonin at approximately a 3:1 ratio. This stronger norepinephrine effect is believed to explain its particular utility in reducing the fatigue component of fibromyalgia and contributes to its cardiovascular side effects (increased heart rate and blood pressure). At therapeutic doses, Milnacipran also exerts mild inhibition of NMDA receptors, which play a role in central pain sensitization.
The FDA label states that the exact mechanism by which Milnacipran improves fibromyalgia symptoms is not known, though the SNRI mechanism is the leading hypothesis. In clinical trials, 37% of patients receiving Milnacipran reported at least a 50% reduction in pain intensity (compared to 14% with placebo), and improvements were also seen in fatigue, physical function, and quality of life measures.
12.5 mg — tablet
Starting dose — used on Day 1 of titration
25 mg — tablet
Used during Days 2-7 of titration schedule
50 mg — tablet
Maintenance dose — taken twice daily (100 mg/day total)
100 mg — tablet
Higher dose option for patients needing dose escalation (maximum 200 mg/day)
Milnacipran is not on any active FDA shortage list as of 2026, but patients frequently report difficulty filling their prescriptions. Several structural factors contribute to this: brand-name Savella has a very high retail price (often $500+ without assistance), generic milnacipran availability is inconsistent at retail pharmacies, and insurance prior authorization requirements delay access for many patients.
Smaller pharmacies often do not routinely stock Milnacipran due to low dispensing volume. Larger chain pharmacies — CVS, Walgreens, Walmart — tend to have more reliable access. Mail-order pharmacies operated through insurance benefit managers typically maintain the most consistent supply and offer 90-day fills that reduce the frequency of access challenges.
When you can't find Milnacipran at your pharmacy, medfinder contacts pharmacies near you to find which ones can fill your prescription — saving you hours of calling on hold. Results are texted directly to you.
Milnacipran is not a controlled substance, which means any licensed prescriber with authority to prescribe medications in their state can write a prescription for it — without DEA registration or other special requirements. This makes it broadly accessible through primary care, specialty care, and telehealth settings.
Types of providers who commonly prescribe Milnacipran include:
Rheumatologists — specialists in fibromyalgia, arthritis, and musculoskeletal conditions
Primary care physicians (PCPs) and family medicine doctors
Neurologists — especially when fibromyalgia overlaps with migraine or neuropathic pain
Pain management specialists
Nurse practitioners (NPs) and physician assistants (PAs) — in most states, NPs and PAs have full prescribing authority for non-controlled medications including Milnacipran
Because Milnacipran is not a controlled substance, it is also fully available through telehealth. Platforms like Klarity Health, Teladoc, MDLive, and others allow patients to consult with licensed providers who can evaluate fibromyalgia symptoms and prescribe Milnacipran remotely — without an in-person visit — as long as the prescriber is licensed in the patient's state.
No. Milnacipran (Savella) is not a controlled substance. The FDA prescribing information explicitly states that Milnacipran is not a DEA-scheduled medication. This means there are no special prescribing restrictions such as DEA registration, quantity limits, or requirements for in-person visits before prescription.
Any licensed prescriber — including physicians, nurse practitioners, and physician assistants — can prescribe Milnacipran. It can also be prescribed via telehealth without the additional requirements that apply to controlled substances like opioids, benzodiazepines, or stimulants. Refill prescriptions can be phoned in, faxed, or sent electronically without the in-person visit requirements that apply to Schedule II-IV substances.
While Milnacipran is in the same drug class (SNRI) as some antidepressants, it does not have the abuse potential or dependence profile of controlled substances. However, physical dependence can develop with long-term use, and the medication should be tapered gradually when discontinuing rather than stopped abruptly.
The following side effects occurred in 5% or more of patients in clinical trials (and more frequently than with placebo):
Nausea (most common — take with food to reduce)
Headache
Constipation
Dizziness
Insomnia
Hot flushes
Excessive sweating (hyperhidrosis)
Vomiting
Palpitations
Increased heart rate
Dry mouth
Elevated blood pressure (hypertension)
Black Box Warning: Suicidal thoughts and behavior in patients under age 24
Serotonin syndrome (life-threatening — emergency)
Liver damage / hepatotoxicity
Seizures
Hyponatremia (low sodium levels)
Urinary retention (especially in male patients)
Mania/hypomania activation
Abnormal bleeding (risk increased with NSAIDs, aspirin, anticoagulants)
Know what you need? Skip the search.
Duloxetine (Cymbalta)
FDA-approved SNRI for fibromyalgia; once-daily dosing; generic widely available and less expensive; also approved for depression, anxiety, and diabetic neuropathy.
Pregabalin (Lyrica)
FDA-approved calcium channel ligand for fibromyalgia; different mechanism than SNRIs; Schedule V controlled substance; generic now available. May cause weight gain and dizziness.
Gabapentin (Neurontin)
Off-label for fibromyalgia; same class as pregabalin; widely available as low-cost generic; not controlled federally; frequently used as step therapy qualifier.
Amitriptyline (Elavil)
Low-dose TCA (10-50 mg) used off-label for fibromyalgia pain and sleep improvement; inexpensive generic; long clinical track record; often used as first-line or bridge therapy.
Prefer Milnacipran? We can find it.
MAOIs (phenelzine, tranylcypromine, selegiline, isocarboxazid)
majorContraindicated — risk of life-threatening serotonin syndrome. Require 14-day washout before starting Milnacipran; 5-day washout after stopping Milnacipran.
Linezolid / IV methylene blue
majorContraindicated — MAOI-like serotonin syndrome risk. Discontinue Milnacipran if linezolid must be given urgently.
SSRIs and other SNRIs
majorIncreased serotonin syndrome risk. Do not combine without medical supervision; careful cross-taper required when switching.
Triptans (sumatriptan, rizatriptan, etc.)
majorSerotonin syndrome risk. Use with caution; notify all prescribers of Milnacipran use.
Epinephrine/norepinephrine (parenteral)
majorContraindicated with IV formulations — risk of paroxysmal hypertension and arrhythmia. Alert anesthesiologists and surgical teams.
IV digoxin
majorShould be avoided — co-administration of Savella and IV digoxin is contraindicated per FDA labeling.
NSAIDs (ibuprofen, naproxen, indomethacin)
moderateIncreased risk of upper GI bleeding when combined. Use with caution; consider acetaminophen for pain relief instead.
Aspirin (including low-dose cardiac aspirin)
moderateIncreased bleeding risk. Discuss risk-benefit with prescriber if taking low-dose aspirin for cardiac protection.
Warfarin / direct anticoagulants (apixaban, rivaroxaban)
moderateIncreased bleeding risk due to combined antiplatelet and anticoagulant effects. Monitor for unusual bleeding.
Clonidine
moderateMilnacipran may reduce antihypertensive effect of clonidine, potentially causing blood pressure to rise.
St. John's Wort
moderateHerbal supplement with serotonergic activity; increases serotonin syndrome risk when combined with Milnacipran. Disclose all supplements to your provider.
Alcohol
moderateNot recommended — Milnacipran can elevate liver enzymes; alcohol worsens this effect. Contraindicated in patients with substantial alcohol use or liver disease.
Milnacipran (Savella) is one of three FDA-approved medications for fibromyalgia and offers a distinct pharmacological profile — particularly its stronger norepinephrine effect — that may make it the right choice for patients whose fibromyalgia is dominated by fatigue and pain. Clinical trials show meaningful pain reduction in a significant subset of patients, with improvements in fatigue, function, and quality of life.
The primary challenges with Milnacipran are cost and access. Brand-name Savella is expensive at retail, and while generic milnacipran exists, its availability at pharmacies is inconsistent. Commercially insured patients can dramatically reduce costs with the Savella Savings Card. Medicare and uninsured patients should explore manufacturer assistance programs and pharmacy discount cards. Proactive refill habits and using mail-order pharmacy can help prevent supply gaps.
If you're having trouble finding Milnacipran at your local pharmacy, medfinder can help. You provide your medication, dosage, and location — medfinder contacts pharmacies near you to find which ones can fill your prescription and texts you the results. It covers all medications, not just shortage drugs.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini